Tarsus to expand eye disease pipeline with up to $800 million Alkeus acquisition
Reuters
Tarsus Pharmaceuticals is acquiring Alkeus Pharmaceuticals in a deal valued at up to $800 million to expand its ophthalmology pipeline. This strategic move aims to bolster Tarsus's capabilities in treating eye diseases through Alkeus's assets and expertise. The acquisition underscores the company's commitment to growing its presence in the vision care market.
All articles from 7 August 2026. Summaries are AI-generated and may contain errors; the linked article is the authority.